Our attorneys have filed a mass tort lawsuit on behalf of sufferers who took the blood thinner Xarelto (rivaroxaban) and suffered serious bleeding events. Pharmaceutical firms, which includes the makers of Xarelto, possess a duty to ensure that their drugs are reasonably secure for use – and failure to accomplish so may be grounds for compensation. Our lawyers are working challenging to obtain those hurt by the drug the compensation they’re entitled to.
Although bleeding is really a widespread complication associated with anticoagulants, it has been alleged that Xarelto is a lot more unsafe than traditional blood thinners simply because no antidote exists to reverse its blood-thinning effects. This signifies that, in the event of an emergency, patients could be at risk for irreversible bleeding difficulties, such as life-threatening internal and gastrointestinal hemorrhaging.
In the event you or a loved one particular suffered a significant bleeding occasion soon after taking Xarelto, you may have legal recourse. For more information, make contact with us these days to have your case reviewed, totally free of charge.
xarelto-compensation-photoThe plaintiffs in these lawsuits are looking for compensation from Bayer and Janssen for previous and future medical bills, lost wages, discomfort and suffering and, in circumstances of death, funeral expenses. Additionally, they may be seeking punitive damages, which are generally awarded to punish the defendant and deter other companies seralta medication from acting similarly.
Why Are Lawsuits Getting Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is unsafe and defective. The plaintiffs claim that, unlike traditional anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Since of this, the lawsuits claim, doctors have no effective indicates of stopping Xarelto users from bleeding in the event of an emergency. Plaintiffs inside the lawsuits allege serious and fatal injuries, including cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior within the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a protected anticoagulant option.
Doctors and health-related staff were not properly made aware of methods to stabilize and treat a Xarelto user in the occasion of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to significant bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing dangerous clotting.
Visit this page for far more data on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys in the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.